### Highlights of This Issue 3097

#### SPECIAL FEATURES

**CCR 20th Anniversary Commentary**

3099  
**CCR 20th Anniversary Commentary: Chimeric Antigen Receptors—From Model T to the Tesla**  
Patrick Hwu

**CCR Translations**

3102  
**Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy**  
Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, and Jennifer A. Wargo  
*See related article, p. 3140*

3105  
**Growth Factor Receptor Fusions Predict Therapeutic Sensitivity**  
Manmeet S. Ahluwalia and Jeremy N. Rich  
*See related article p. 3307*

**Molecular Pathways**

3108  
**Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy**  
Diletta Di Mitri, Alberto Toso, and Andrea Alimonti

**Reviews**

3113  
**Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy**  
Atsushi Yonezawa, Suparna Dutt, Cariad Chester, Jeewon Kim, and Holbrook E. Kohrt

3121  
**Nanotechnology: Future of Oncotherapy**  
Kshipra M. Gharpure, Sherry Y. Wu, Chun Li, Gabriel Lopez-Berestein, and Anil K. Sood

**CANCER THERAPY: CLINICAL**

3140  
**PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients**  
*See related commentary, p. 3102*

3149  
**Phase I Hepatic Immunotherapy for Metastases Study of Intravenous Chimeric Antigen Receptor—Modified T-cell Therapy for CEA* Liver Metastases**  

3160  
**Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma**  
Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, and Farrukh T. Awan

3170  
**Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Ablative Prostate Cancer Patients**  
Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, and Partha Nandy

3178  
**Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines**  
John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allsop, Catia Fonseca, Yukoh Nakazaki, David Nemer, Chandrakit P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, and Glenn Dranoff

**PERSONALIZED MEDICINE AND IMAGING**

3187  
**Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group**  
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok, Yi-Long Wu, Jin Soo Lee, Chong-Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Melilin Liao, Yunzhong Zhou, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, and Lin Wu

Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas
Misu Lee, Tobias Wiedemann, Claudia Gross, Ines Leinhäuser, Federico Roncaroli, Rickmer Braren, and Natalia S. Pellegrata

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Robbie Carson, Basak Celikci, Cathy Fenning, Arman Javadi, Nyree Crawford, Lucia Perez-Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, and Sandra Van Schaeybroeck

Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma

An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Jyoti Asundi, Lisa Crocker, Jarrod Tremayne, Peter Chang, Chie Sakakana, Josh Tanguay, Susan Spencer, Anubhav Chalasani, Elizabeth Luis, Karen Gascoigne, Rupal Desai, Rajiv Raja, Brad A. Friedman, Peter M. Haverty, Paul Polakis, and Ron Firestein

Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate
Preethi Korangath, Wei Wen Teo, Helen Sadik, Liangfeng Han, Noriko Mori, Charlotte M. Huijts, Horne Wildes, Santosh Bharti, Zhe Zhang, Cesar A. Santa-Maria, Hualing Tsai, Chi V. Dang, Vered Stearns, Zaver M. Bhujwalla, and Saraswati Sukumar

The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment

XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A

A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Shang-Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan Spencer, Helga Raab, Robert Soriano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso, Paul Polakis, John Flygare, and Andrew G. Polson

Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Anna Luisa Di Stefano, Alessandra Fucci, Veronique Fattini, Marianne Labussiere, Karima Mokhtari, Pietro Zoppoli, Yannick Marie, Aurelie Bruno, Blandine Boisselier, Marine Giry, Julien Savatovsky, Mehdi Touat, Hayat Belaid, Aurelie Kamoun, Ahmed Idlibi, Caroline Houillier, Feng R. Luo, Jean Charles Soria, Josep Tabernero, Marica Eoli, Rosina Paterra, Stephen Yip, Kevin Petrcca, Jennifer A. Chan, Gaetano Finocchiaro, Anna Lasorella, Marc Sanson, and Antonio Iavarone

Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting
Hongda Chen, Manuela Zucknick, Simone Werner, Phillip Knebel, and Hermann Brenner
Table of Contents

3327 Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

3340 Genetic Modulation of Neurocognitive Function in Glioma Patients
Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurter, Nicholas Boehling, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, and Jeffrey S. Wefel

3347 POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

CORRECTIONS

3356 Correction: Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

3358 Correction: A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

3359 Correction: CTLA4 Blockade Broadens the Peripheral T-cell Receptor Repertoire

ABOUT THE COVER

The heatmap shows expression of immune-related genes in endometrial cancers from the TCGA series. POLE proofreading-mutant tumors display evidence of a robust cytotoxic T-cell response. For details, see the article by van Gool and colleagues on page 3347 of this issue.